These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16192780)

  • 1. Propofol: the challenges of formulation.
    Baker MT; Naguib M
    Anesthesiology; 2005 Oct; 103(4):860-76. PubMed ID: 16192780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new generation of propofol.
    Wang H; Cork R; Rao A
    Curr Opin Anaesthesiol; 2007 Aug; 20(4):311-5. PubMed ID: 17620837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-β-Cyclodextrin.
    Goodchild CS; Serrao JM; Kolosov A; Boyd BJ
    Anesth Analg; 2015 May; 120(5):1025-1031. PubMed ID: 25517195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug, fospropofol disodium: a propofol prodrug.
    Welliver M; Rugari SM
    AANA J; 2009 Aug; 77(4):301-8. PubMed ID: 19731849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free radical and drug oxidation products in an intensive care unit sedative: propofol with sulfite.
    Baker MT; Gregerson MS; Martin SM; Buettner GR
    Crit Care Med; 2003 Mar; 31(3):787-92. PubMed ID: 12626985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical properties and stability of two emulsion formulations of propofol.
    Han J; Davis SS; Washington C
    Int J Pharm; 2001 Mar; 215(1-2):207-20. PubMed ID: 11250106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfite supported lipid peroxidation in propofol emulsions.
    Baker MT; Dehring DJ; Gregerson MS
    Anesthesiology; 2002 Nov; 97(5):1162-7. PubMed ID: 12411802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetically stable propofol emulsions with reduced free drug concentration for intravenous delivery.
    Damitz R; Chauhan A
    Int J Pharm; 2015; 486(1-2):232-41. PubMed ID: 25839419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel lipid and preservative-free propofol formulation: properties and pharmacodynamics.
    Ravenelle F; Gori S; Le Garrec D; Lessard D; Luo L; Palusova D; Sneyd JR; Smith D
    Pharm Res; 2008 Feb; 25(2):313-9. PubMed ID: 18030606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions.
    Nemec K; Germ E; Schulz-Siegmund M; Ortner A
    Pharmazie; 2009 Feb; 64(2):94-7. PubMed ID: 19320281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative canine pharmacokinetics-pharmacodynamics of fospropofol disodium injection, propofol emulsion, and cyclodextrin-enabled propofol solution following bolus parenteral administration.
    McIntosh MP; Rajewski RA
    J Pharm Sci; 2012 Sep; 101(9):3547-52. PubMed ID: 22581759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanostructured Lipid Carrier of Propofol: a Promising Alternative to Marketed Soybean Oil-Based Nanoemulsion.
    Shevalkar G; Pai R; Vavia P
    AAPS PharmSciTech; 2019 May; 20(5):201. PubMed ID: 31139968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pain on injection of lipid-free propofol and propofol emulsion containing medium-chain triglyceride: a comparative study.
    Dubey PK; Kumar A
    Anesth Analg; 2005 Oct; 101(4):1060-1062. PubMed ID: 16192520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel propofol derivatives and implications for anesthesia practice.
    Feng AY; Kaye AD; Kaye RJ; Belani K; Urman RD
    J Anaesthesiol Clin Pharmacol; 2017; 33(1):9-15. PubMed ID: 28413268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propofol: an immunomodulating agent.
    Marik PE
    Pharmacotherapy; 2005 May; 25(5 Pt 2):28S-33S. PubMed ID: 15899746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propofol in a modified cyclodextrin formulation: first human study of dose-response with emphasis on injection pain.
    Wallentine CB; Shimode N; Egan TD; Pace NL
    Anesth Analg; 2011 Oct; 113(4):738-41. PubMed ID: 21890884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and Evaluation of Multidose Propofol Nanoemulsion Using Statistically Designed Experiments.
    Hota SS; Pattnaik S; Mallick S
    Acta Chim Slov; 2020 Mar; 67(1):179-188. PubMed ID: 33558914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of an emulsion formulation of ICI 35 868.
    Glen JB; Hunter SC
    Br J Anaesth; 1984 Jun; 56(6):617-26. PubMed ID: 6202310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Micro to macro (M2M)"--A novel approach for intravenous delivery of propofol.
    Damitz R; Chauhan A
    Int J Pharm; 2015 Oct; 494(1):218-26. PubMed ID: 26260228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of a new formulation of propofol in a medium-chain and long-chain triglycerides emulsion in dogs.
    Redondo García JI
    J Vet Pharmacol Ther; 2007 Aug; 30(4):288-94. PubMed ID: 17610401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.